Johnson & Johnson Invests $1 Billion in Cell Therapy Manufacturing Facility

Johnson & Johnson announced a more than US$1 billion investment in a new US facility for cell therapy manufacturing. The new facility in Montgomery County, Pennsylvania will cater to next generation cell therapy manufacturing for various indications including cancer, immune-mediated and neurological diseases. This investment further strengthens the company's portfolio and is part of its broader plans to invest more than US$55 billion in a four-year margin across manufacturing, research and development, and technology through to 2029.

The expansion comes as companies are increasingly developing therapies involving viral vectors, oligonucleotides, antibody-drug conjugates, and cell-based therapies such as CAR T. Each modality introduces new manufacturing challenges, from product instability to contamination risks and process variability. Unlike traditional manufacturing, where the process is relatively stable, and efficiencies build over time, biologics and advanced therapies require specialized approaches.

One of the biggest challenges facing advanced therapy manufacturing is workforce readiness. Manufacturing biologics and cell-based therapies takes place in highly regulated Good Manufacturing Practice (GMP) environments where employees must be trained not only in science, but also in complex operational procedures. "In many facilities, bringing someone from the front door to the factory floor can take as long as 18 months before they're fully operational," said Darrin Morrissey, CEO of the National Institute for Bioprocessing Research and Training (NIBRT).

NIBRT was established nearly two decades ago with government backing to address workforce training challenges. The institute operates a simulated GMP manufacturing environment equipped with the same equipment used in commercial biologics facilities, allowing employees to train in realistic production scenarios before stepping into real manufacturing plants. In 2025, NIBRT taught more than 4,800 trainees, supporting biopharma manufacturing operations across Ireland and internationally.

In other manufacturing developments, Swiss biotechnology company NewBiologix S.A. has detailed the generation and characterization of its proprietary clonal HEK293 cell line, NBX1P01, in a peer-reviewed publication. According to the paper, NBX1P01 supports rapid, effective and scalable production of viral vectors – an important factor in gene therapy manufacturing. The cell line demonstrated a two-fold higher full-to-empty capsid ratio compared to a leading commercial HEK293 cell line, genome stability over 55 population doubling levels, genome integrity with more than 70% intact rAAV genomes with minimal encapsidated contaminating DNA, and consistent performance across production volumes.

Additionally, Cellares will be supporting the clinical production and regulatory advancement of the University of Wisconsin School of Medicine and Public Health's CRISPR-edited GD2 CAR-T investigational therapy for solid tumors. The GD2 CAR-T program uses CRISPR gene editing to modify patient T cells via electroporation. Initially focused on high-grade gliomas, the therapy could inform future studies into GD2+ cancers such as neuroblastoma, osteosarcoma and melanoma, which have limited therapeutic options for refractory or relapsed cases.